Abstract
A new periodontitis classification scheme has been adopted, in which forms of the disease previously recognized as “chronic” or “aggressive” are now grouped under a single category (“periodontitis”) and are further characterized based on a multi‐dimensional staging and grading system. Staging is largely dependent upon the severity of disease at presentation as well as on the complexity of disease management, while grading provides supplemental information about biological features of the disease including a history‐based analysis of the rate of periodontitis progression; assessment of the risk for further progression; analysis of possible poor outcomes of treatment; and assessment of the risk that the disease or its treatment may negatively affect the general health of the patient.
Necrotizing periodontal diseases, whose characteristic clinical phenotype includes typical features (papilla necrosis, bleeding, and pain) and are associated with host immune response impairments, remain a distinct periodontitis category.
Endodontic‐periodontal lesions, defined by a pathological communication between the pulpal and periodontal tissues at a given tooth, occur in either an acute or a chronic form, and are classified according to signs and symptoms that have direct impact on their prognosis and treatment.
Periodontal abscesses are defined as acute lesions characterized by localized accumulation of pus within the gingival wall of the periodontal pocket/sulcus, rapid tissue destruction and are associated with risk for systemic dissemination.
| Original language | English |
|---|---|
| Pages (from-to) | S162-S170 |
| Number of pages | 9 |
| Journal | Journal of Clinical Periodontology |
| Volume | 45 |
| Issue number | SI |
| DOIs | |
| Publication status | Published - 20 Jun 2018 |
| Event | Workshop on the Classification of Periodontal and Peri‐Implant Diseases and Conditions - Duration: 20 Jun 2018 → … |
Bibliographical note
In special issue: Proceedings of the World Workshop on the Classification of Periodontal and Peri‐Implant Diseases and Conditions. The proceedings of the workshop were jointly and simultaneously published in the Journal of Periodontology and Journal of Clinical Periodontology.Funding
Workshop participants filed detailed disclosure of potential conflicts of interest relevant to the workshop topics, and these are kept on file. The authors receive, or have received, research funding, consultant fees, and/or lecture compensation from the following companies: 3M, Amgen, CardioForecast, Colgate, Dentaid, Dentium, Dentsply Sirona, Dexcel Pharma, EMS Dental, GABA, Geistlich, GlaxoSmithKline, Hu-Friedy, IBSA Institut Biochimique, Interleukin Genetics, Izun Pharmaceuticals, Johnson & Johnson, Klockner, Menarini Ricerche, MIS Implants, Neoss, Nobel Biocare, Noveome Biotherapeutics, OraPharma, Osteology Foundation, Oxtex, Philips, Procter & Gamble, Sanofi-Aventis, Straumann, SUNSTAR, Sweden & Martina, Thommen Medical, and Zimmer Biomet. planned and conducted jointly by the American Academy of Periodontology and the European Federation of Periodontology with financial support from the American Academy of Periodontology Foundation, Colgate, Johnson & Johnson Consumer Inc., Geistlich Biomaterials, SUNSTAR, and Procter & Gamble Professional Oral Health.
| Funders | Funder number |
|---|---|
| European Federation of Periodontology | |
| Geistlich Biomaterials | |
| Johnson and Johnson | |
| Procter and Gamble | |
| American Academy of Periodontology Foundation | |
| Colgate University |
